FDA’s first clearance of AI for autonomous detection of diabetic retinopathy
A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices.
Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy.
The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.
IDx-DR exceeded all pre-specified superiority endpoints in sensitivity, the ability to correctly identify a patient with disease; specificity, the ability to correctly classify a person as disease-free; and imageability, or the capability to produce quality images of the retina and determine the severity of the disease.
“The AI system’s primary role is to identify those people with diabetes who are likely to have diabetic retinopathy that requires further evaluation by an eye-care provider. The study results demonstrate the safety of autonomous AI systems to bring specialty-level diagnostics to a primary care setting, with the potential to increase access and lower cost,” says Michael Abràmoff, MD, PhD, the Robert C. Watzke Professor of Ophthalmology and Visual Sciences with UI Health Care and principal investigator on the study. He is founder and president of IDx, the company that created the IDx-DR system and funded the study.
Early detection may prevent vision loss
More than 24,000 people in the United States lose their sight to diabetic retinopathy each year. Early detection and treatment can reduce the risk of blindness by 95 percent, but less than 50 percent of patients with diabetes schedule regular exams with an eye-care specialist.
In the study, 900 adult patients with diabetes—but no history of diabetic retinopathy—were examined at 10 primary care sites across the country. Retinal images of the patients were obtained using a robotic camera, with an AI assisting the operator in getting good quality images.
Once the four images were complete, the diagnostic AI then made a clinical diagnosis in 20 seconds. The diagnostic AI detects disease just as expert clinicians do, by having detectors for the lesions characteristic for diabetic retinopathy, including microaneurysms, hemorrhages, and lipoprotein exudates.
Camera operators in the study were existing staff of the primary care clinics, and not physicians or trained photographers.
“This was much more than just a study testing an algorithm on an image. We wanted to test it in the places where it will be used, by the people who will use it, and we compared it to the highest standard in the world,” says Abràmoff, who also holds faculty appointments in the UI College of Engineering.
AI measured against gold standard
Study participants also had retinal images taken at each of the primary care clinics using specialized widefield and 3D imaging equipment without AI and operated by experienced retinal photographers certified by the Wisconsin Fundus Photograph Reading Center (FPRC)—the gold standard in grading the severity of diabetic retinopathy.
Complete diagnostic data accomplished by both the AI system and FPRC readers was available for 819 of the original 900 study participants. FPRC readers identified 198 participants with more than mild diabetic retinopathy who should be further examined by a specialist; the AI was able to correctly identify 173 of the 198 participants with disease, resulting in a sensitivity of 87 percent. Among the 621 disease-free participants identified by FPRC readers, AI identified 556 participants, for a specificity of 90 percent. The AI had a 96 percent imageability rate: of the 852 participants who had an FPRC diagnosis, 819 had an AI system diagnostic output.
The Latest on: IDx-DR
via Google News
The Latest on: IDx-DR
- Digital Diagnostics to Become a Florida Association of ACOs Memberon September 16, 2021 at 2:48 pm
FLAACOs welcomes Digital Diagnostics as their newest strategic member. St. Johns, FL September 16, 2021 --(PR.com)-- Florida Association of ACOs (FLAACOs), a ValueH organization and one of the ...
- Digital Diagnostics to Become a Florida Association of ACOs Memberon September 16, 2021 at 12:00 am
Florida Association of ACOs (FLAACOs), a ValueH organization and one of the leading voices for value-based care announces Digital Diagnostics, developers of IDx-DR, an FDA De Novo-cleared autonomous ...
- Konica Minolta Precision Medicine Announces Name Change to REALM IDx™on September 15, 2021 at 7:53 am
Konica Minolta Precision Medicine (KMPM), a majority-owned subsidiary of Konica Minolta, Inc., announced today that it has changed its name to REALM IDx, Inc. The name change reflects the company’s ...
- Konica Minolta Precision Medicine Announces Name Change to REALM IDxtmon September 15, 2021 at 7:20 am
Konica Minolta Precision Medicine (KMPM), a majority-owned subsidiary of Konica Minolta, Inc., announced today that it has changed its name to REALM IDx, Inc. The name change reflects the company's ...
- Konica Minolta Precision Medicine Announces Name Change to REALM IDx™on September 15, 2021 at 7:07 am
"We're excited to announce the name change," said Dr. Aaron Elliott, Chief Executive Officer of REALM IDx, Inc.. "Our new name reflects not only our focus on advancing integrated diagnostics ...
- Differential Evolution Optimizationon September 10, 2021 at 9:49 pm
Dr. James McCaffrey of Microsoft Research explains stochastic gradient descent (SGD) neural network training, specifically implementing a bio-inspired optimization technique called differential ...
- DGAP-PVR: Allianz SE: Release according to -4-on September 6, 2021 at 2:44 am
13:15 AMUNDI INDEX BARCLAYS GLOBAL AGG 500M UCITS ETF DR - EUR: Net Asset Value(s) Amundi Index Barclays Globa 52,74 +0,12% 13:15 AMUNDI INDEX SOLUTIONS AM IDX US CORP SRI UCITSETF: Net Asset ...
- Amundi Amundi Idx Sol Prime UK Mid and small Cap UETF DR Dis GBPon August 31, 2021 at 5:00 pm
Performance as at 02/09/2021. Performance figures are shown in Pound sterling (GBP). Total return performance figures are calculated on a bid price to bid price basis (mid to mid for OEICs) with ...
- Integral Diagnostics posts double-digit earnings and profit growthon August 27, 2021 at 12:05 am
IDX has not profited from JobKeeper and voluntarily repaid $2.9 million of JobKeeper in June 2021. Dr Kadish warned that the pandemic and associated government responses will continue to have an ...
- Fonville, Jameson August 19, 2021 at 5:00 pm
In 1952, they moved to 5201 Glenridge Dr. in Sandy Springs. Jim attended Slaton Grammar School, E. Rivers Grammar School and was a member of the first class to go the full five years of high ...
via Bing News